Clinical trials have shown that the nonthienopyridine P2Y12 antagonists such as Ticagrelor and Cangrelor were associated to lower incidence of cardiovascular mortality, AMI, or stroke compared with the thienopyridine P2Y12 antagonists, Clopidogrel and Prasugrel [9]. The gene discussed is P2RY12; the disease is Stroke.